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COMPOSITION OF, METHOD OF PRODUCING 
AND METHOD OF USING A STABILIZED 
FORMULATION FOR ASSAYING PEROXIDASE 
ACTIVITY 
TECHNICAL FIELD 
The present invention relates generally to assaying 
peroxidase activity and more particularly to a stabilized 
formulation for use in such activity and a method of 
making the formulation. 
BACKGROUND OF THE INVENTION 
Many assay procedures utilize enzymes as catalysts 
for analytical reactions. In particular, the enzyme per 
oxidase is among the most commonly used in enzymatic 
detection reactions. 
Peroxidases are widespread in nature, being found 
particularly in a variety of plants. They appear to cata 
lyze the same reaction, but differ markedly in physico 
chemical and kinetic properties. Three main types of 
peroxidases have been identi?ed: acidic peroxidases 
with very high carbohydrate content; neutral or slightly 
basic peroxidases of medium sugar content; and very 
basic peroxidases of low sugar content. Among these 
peroxidases, the C isozyrne of horseradish peroxidase is 
most commonly encountered in biotechnology. 
Horseradish peroxidase is popularly used in labeling 
haptens, antibodies, protein A/G, avidin/streptavidin 
and DNA for enzyme immunoassay, immunocytochem 
istry, immunoblot and DNA detection. Detection of 
enzyme activity in the assay procedures takes advan 
tage of the reactive cooperation between the enzyme 
and a highly sensitive color-forming agent or chromatic 
compound. The chromatic compound is a hydrogen 
donor that changes color due to the loss of hydrogen 
atoms. The dehydrogenation occurs in the presence of 
an oxidizing agent, typically hydrogen peroxide 
(H202). It is this oxidation reaction that is catalyzed by 
the peroxidase. Since a colored product results from the 
reaction catalyzed by the enzyme, the peroxidase activ 
ity is determined from the intensity of the color gener 
ated. 
Thus, in a typical assay protocol, the peroxidase is 
?rst introduced to the test medium. Then the chromatic 
compound and H202 are mixed to form a colorless 
substrate that is added to the medium to test for the 
enzyme. The chromatic compound as substrate under 
goes an oxidation reaction when catalyzed by peroxi 
dase in the presence of H202. A colored product results 
from the removal of hydrogen from the chromatic com 
pound. The colored product is easily measured by spec 
trophotometry. 
Many different types of chromatic compounds have 
been used in peroxidase assay procedures. When choos 
ing a chromatic compound to be used in combination 
with H201 as a peroxidase substrate, it is desired that 
there be a high rate of oxidation and thus a high rate of 
color conversion. It is further desired that the product 
have a stable color for easy spectrophotometric mea 
surement. Examples of known chromatic compounds 
suitable as hydrogen donors are o-dianisidine, guaiacol, 
S-arninosalicylic acid, 2,2'-azino-di-(3-ethyl-benzthiazo 
line-6-sulfonate) (ABTS), o-phenylenediarnine (OPD) 
and l,2-benzenediamine. These chromatic compounds 
have certain disadvantages such as high basal oxidation 
or poor stability of oxidized product or are mutagenic. 
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Accordingly, an alternative chromatic compound that 
overcomes these disadvantages is preferred. 
One group of chromatic compounds found to over 
come the disadvantages described above is of the benzi 
dine type, particularly tetraalkybenzidine or salts 
thereof. The most successfully used compound of this 
type is 3,3',5,5’-tetramethylbenzidine (TMB). This com 
pound was synthesized in 1974 and found to have suffi 
cient color sensitivity for use in peroxidase assays and in 
addition has been shown to desirably be noncarcino 
genic (Garner et al., Cancer Letters 1, 39-42 (1975); 
Garner et al., J. Forensic Sci. 21, 8l6—82l (1976)). These 
qualities have popularized TMB to become the chro 
matic compound of choice for use as a substrate for 
peroxidase assay (Bos et a1 , J. Immunoassay 2, 187-204 
(1981)). 
While TMB provides many desirable qualities for use 
as a chromatic compound, it has the disadvantage of 
low ‘stability. Hydrogen peroxide has also long been 
known to be relatively unstable in solution. Accord 
ingly, early use of the reagents as a combined substrate 
involved mixing them together at the time of the proce 
dure and then introducing the combination to the test 
medium. Such a procedure is relatively inconvenient 
and has been known to lead to inadvertent mixing errors 
that directly result in incorrect test results. 
Artisans have tried in the past to produce a combined 
chromatic compound/peroxide substrate in advance of 
the test procedure but the same low stability of the 
substrate mixture was found. More particularly, when 
the TMB and H202 cannot coexist as a substrate formu 
lation for extended periods of time. This is because of 
the spontaneous evolution of color occurring due to the 
decomposition of the peroxide to give oxygen radicals, 
that attract hydrogen atoms from the chromatic com 
pound. This occurs even in the absence of a catalyst 
such as peroxidase. Thus the substrate solution becomes 
useless in a relatively short time period. 
Attempts have been made to find a stabilizing agent 
that prevents the substrate solution containing both a 
chromatic compound and peroxide from deteriorating 
when prepared and stored in a single container. One 
such attempt is disclosed in U.S. Pat. No. 4,891,314 to 
Pauly et al. The stabilizing agent utilized in the Pauly 
formulation is penicillin. While the formulation includ 
ing the penicillin showed improvement over the prior 
art by providing some stabilization of the substrate for 
mulation, it is not without its drawbacks and limitations. 
More particularly, it is disclosed that the addition of 
penicillin provides only a relatively limited increase in 
stability for one to several weeks. It has also been found 
that color sensitivity can be improved over the formula 
tion using penicillin as the stabilizing agent. 
Thus a need is identi?ed to find a formulation for use 
as a substrate for assaying peroxidase activity that con 
tains a chromatic compound, peroxide and a stabilizing 
agent that provides increased stabilization and color 
sensitivity. The present invention is shown to satisfy 
that need. 
SUMMARY OF THE INVENTION 
Accordingly, it is a primary object of the present 
invention to provide a formulation for use as a substrate 
for assaying peroxidase activity that overcomes the 
drawbacks and disadvantages of the prior art. 
Another object of the present invention is to provide 
a stabilized chromatic compound/peroxide formulation 
for use as a substrate in assaying peroxidase activity that 
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saves storage space by eliminating the need to maintain 
separate containers of the individual reagents. 
It is a further object of the present invention to pro 
vide a chromatic compound/peroxide formulation for 
use as a substrate in assaying peroxidase activity which 
eliminates the need to mix the individual reagents at the 
time of the test procedure and hence is more convenient 
to use. 
It is an additional object of the present invention to 
provide a combined chromatic compound/peroxide 
formulation for use in assaying peroxidase activity that 
exhibits signi?cantly improved stability. 
Another object of the present invention is to provide 
a chromatic compound/peroxide formulation for use as 
a substrate in assaying peroxidase activity that provides 
enhanced detection sensitivity. ' 
It is still a further object of the present invention is to 
provide a chromatic compound/peroxide formulation 
for use as a substrate in assaying peroxidase activity that 
provides longer storage life than is available with prior 
art formulations. 
Other objects and advantages of the present invention 
will become apparent as the description thereof pro 
'ceeds. 
In satisfaction of the foregoing objects and advan 
tages, there is provided by this invention a formulation 
for use as a substrate in assaying peroxidase activity 
including a chromatic compound, a peroxide and a 
stabilizing agent selected from a group including baci 
tracin, its precursor, bacitracin components derived by 
hydrolysis or any mixtures thereof. The use of bacitra 
cin or its family as a stabilizing agent allows the sub 
strate solution to be prepared in advance of the assay 
procedures and stored for months without deterioration 
of the reactive components. 
The chromatic compound used in the inventive sub 
strate formulation is selected from a group consisting of 
tetraalkylbenzidine, salts of tetraalkylbenzidine or any 
mixtures thereof. The preferred substrate is 3,3',5,5’-tet 
ramethylbenzidine (TMB). 
The TMB is dissolved in a water-miscible organic 
solvent to form a ?rst solution. Examples of solvents 
suitable for use include dimethyl sulfoxide (DMSO), 
dimethyl formamide, dioxane or tetrahydrofuran. The 
TMB is most commonly dissolved in DMSO. 
A second solution including the stabilizing agent is 
prepared to mix with the ?rst solution to form the ?nal 
formulation. An aqueous buffer solution is prepared 
utilizing an acidic buffer substance. Such buffers as 
citrate, acetate and phosphate may be employed as the 
buffer substance. The buffer is utilized to adjust the pH 
of the ?nal formulation to the optimum level for storage 
and use. 
The stabilizing agent in the form of a bacitracin com 
pound is added to the aqueous buffer solution. It is 
commonly known in the art that bacitracin is a peptide 
chain including a series of amino acids. A bacitracin 
precursor, i.e. a longer peptide chain including the basic 
bacitracin constituents, may also be utilized. The use of 
bacitracin components, i.e. The parent bacitracin pep 
tide chain broken down into smaller peptide chains by 
hydrolysis, is also suggested. 
A peroxide either in liquid or solid form is added to 
the aqueous buffer solution including the stabilizing 
agent. Typically, hydrogen peroxide or, alternatively, 
urea hydrogen peroxide is used as the liquid or solid 
peroxide, respectively. The TMB solution and the 
peroxide/bacitracin solution, made at room tempera 
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ture, are then thoroughly mixed together and stored in 
an amber bottle at 4° C. in a dark place. The stabilized 
formulation is ready to be conveniently utilized in a 
peroxidase enzyme assay or enzyme immunoassay as 
desired. 
In a typical enzyme linked irnmunosorbent assay 
(ELISA) test, a test sample to be checked ‘for the pres 
ence of an antigen is introduced into an assaying envi 
ronment or microwell containing antibodies specific for 
the antigen along with antigen-peroxidase conjugate. If 
the antigen is present in good concentration, it prevents 
the antigen-peroxidase conjugate from binding to the 
immobilized antibodies. However, if the antigen is pres 
ent in low concentration, a greater amount of antigen 
peroxidase conjugate is bound to the antibodies. 
After a period of incubation, the microwell is washed 
to remove any unbound antigen-peroxidase conjugate. 
The colorless substrate formulation containing H102 
and the chromatic compound is then added. The test 
sample and formulation is then examined for the pres 
ence or absence of color. Any antigen-peroxidase con 
jugate bound to the antibodies in the test sample cata 
lyzes the oxidation between H202 and the chromatic 
compound, resulting in the evolution of a colored prod 
uct. The optical density of the colored product is mea 
sured and compared to calibration tables to determine 
the extent of peroxidase activity. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As indicated above, this invention relates to an inno 
vative and novel stabilized substrate formulation for use 
in assaying peroxidase activity. The resulting formula 
tion may be stored in solution over long periods of time 
and provides enhanced color sensitivity for excellent 
results in the assay procedure. 
The formulation is formed of a mixture of two solu 
tions. The ?rst solution includes a chromatic com 
pound. Preferably, the chromatic compound is selected 
from a group consisting of tetraalkylbenzidine, salts of 
tetraalkylbenzidine or any mixtures thereof. The most 
popular chromatic compound is 3,3',5,5’-tetramethyl 
benzidine (T MB). This compound can be obtained from 
Aldrich Chemical Company or Sigma Chemical Com 
pany. 
The TMB is dissolved in a water-miscible organic 
solvent. While such solvents as dimethyl formamide, 
dioxane or tetrahydrofuran may be employed, the pre 
ferred solvent is dimethyl sulfoxide (DMSO). The TMB 
is typically dissolved in DMSO at a concentration of 
between 25 mM and 33 mM. 
The second solution includes a stabilizing agent and 
an acidic buffer substance. The buffer substance may be, 
for example, chosen from a group consisting of citrate, 
acetate and phosphate or mixtures thereof. Preferably 
citrate is used to adjust the pH. When the ?nal formula 
tion is prepared, the pH generally falls within a range 
between 2.5 and 6.0, and most desirably, between 3.0 
and 4.0. 
The stabilizing agent used in the invention substrate 
formulation is bacitracin, such as may be obtained also 
from Aldrich Chemical Company or Sigma Chemical 
Company. Since bacitracin is a peptide chain including 
a series of amino acids, a longer peptide chain including 
the basic bacitracin constituents (i.e. a bacitracin pre 
cursor) may be used. Further, bacitracin components, 
formed by the breakdown of the parent bacitracin struc 
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ture into smaller peptide chains and components by 
hydrolysis, may also be used. 
A peroxide for use as an oxidizing agent in the assay 
reaction is added to the second solution. A liquid perox 
ide in the form of hydrogen peroxide or a solid perox 
ide, such as urea hydrogen peroxide, may be used. 
The two solutions are prepared at room temperature 
and mixed together thoroughly. The ratio between the 
organic solvent and the aqueous buffer solution includ 
ing the peroxide and stabilizing agent is preferably in 
the range between 1:99 and 35:65. The formulation is 
stored in an amber bottle at 4° C. and has been shown to 
remain stable for a period of several months. The stabi 
lized formulation is ready for use at any time an assay is 
conducted. The ?nal concentration ranges of the com 
ponents of the formulation are as follows: 
Chromatic compound: 1.0 mM-1.75 mM 
Stabilizing agent: 0.5 mM-2.0 mM 
Peroxide: 2 mM-lO mM 
Buffer: 25 mM-lOO mM 
The following example is presented to illustrate the 
invention but it is not to be considered as limited 
thereto. 
EXAMPLE 
Citric acid monohydrate (3.60 gm) and trisodium 
citrate dihydrate (1.838 gm) was dissolved in 950 ml of 
double-distilled water. Bacitracin (1.422 gm) was then 
added with stirring until it dissolved. Urea hydrogen 
peroxide (0.564 gm) was added to the above with con 
tinuous stirring. 3,3',5,5'-Tetramethylbenzidine (300 
mg) was ?rst completely dissolved in 50 ml of dimethyl 
sulfoxide before adding to the above solution. After 
thorough mixing in an amber bottle the solution was 
ready for use or storage at 4° C. The ?nal concentra 
tions of each of the above components was: bacitracin, 
1.0 mM; urea hydrogen peroxide, 6 mM; TMB, 1.25 
mM; DMSO, 5%; citrate, 25 mM and the ?nal pH was 
3.4. 
The above substrate solution was examined for its 
stabilityat various temperatures. Table I indicates the 
absorbance reading at 650 nm when the solution was 
incubated at 4° C., 37° C. or 97° C. for the indicated 
length of time and then 100 ul of the aliquots were 
allowed to react with 100 pg of horseradish peroxidase 
(HRP) at room temperature for 10 min. The absorbance 
reading was stabilized by adding 100 ul of 1 M phos 
phoric acid and determined at 450 nm. 
TABLE l 
EFFECT OF DIFFERENT TEMPERATURES 
ON SUBSTRATE STABILITY 
(Absorbance at 650 nm after 
10 minutes incubation at room temperature) 
zero time 30 days 60 days 
4' C. — HRP 0.037 0.038 0.040 
+I-IRP 1.251 1.230 1.212 
zero time 5 days 10 days 
37' C —l-IRP 0.037 0.040 0.045 
+HRP 1.230 1.191 1.173 
zero time 2 hours 4 hours 
97' C. —HRP 0.037 0.041 0.046 
+HRP L470 1.405 1.005 
The absorbance values in Table 1 clearly show the 
excellent color sensitivity of the substrate formulation. 
With reference to the formulation sample stored at 4° 
C., there was a signi?cant distinction between readings 
0 
20 
25 
40 
45 
50 
55 
65 
6 
indicating enzymatic and non-enzymatic activity even 
after sixty days of storage. ' 
In summary, numerous bene?ts have been described 
which result from employing the concept of the present 
invention. A novel stabilized formulation for use as a 
substrate in assaying peroxidase activity is disclosed. 
This formulation includes a chromatic compound such 
as TMB in solution with H202 and a stabilizing agent 
from the bacitracin family. The formulation provides 
for longer storage life for the combination than seen in 
the prior art. The formulation also enhances the detec 
tion sensitivity during the assay procedure. . 
The invention has been described herein with refer 
ence to certain preferred embodiments. However, as 
obvious variations thereon will become apparent to 
those skilled in the art, the invention is not to be consid 
ered as limited thereto. 
I claim: 
1. A formulation for the detection and determination 
of peroxidase activity, comprising: 
a chromatic compound; 
a peroxide; > 
a water-miscible organic solvent; 
an aqueous buffer solution; and 
a stabilizing agent selected from a group consisting of 
bacitracin, bacitracin precursors, bacitracin com 
ponents derived by hydrolysis and mixtures 
thereof. 
2. The formulation set forth in claim 1 wherein said 
chromatic compound is selected from a group consist 
ing of tetraalkylbenzidine, salts of tetraalkylbenzidine 
and mixtures thereof. 
3. The formulation set forth in claim 1 wherein said 
chromatic compound is 3,3',5,5'-tetramethylbenzidine. 
4. The formulation set forth in claim 1 wherein said 
water-miscible organic solvent is selected from a group 
consisting of dioxane, tetrahydrofuran, dimethyl sulfox 
ide, dimethyl formamide and mixtures thereof. 
5. The formulation set forth in claim 1 wherein said 
buffer is an acidic buffer selected from a group consist 
ing of citrate, acetate, phosphate and mixtures thereof. 
6. The formulation set forth in claim 1 wherein a ratio 
between said organic solvent and said aqueous solution 
is between 1:99 and 35:65 volume percent. 
7. The formulation set forth in claim 1 wherein a ?nal 
concentration of said chromatic compound is between 
1.0 mM and 1.75 mM. 
8. The formulation set forth in claim 1 wherein a final 
concentration of said peroxide is between 2.0 mM and 
10.0 mM. 
9. The formulation set forth in claim 1 wherein a ?nal 
concentration of stabilizing agent is between 0.5 mM 
and 2.0 mM. 
10. The formulation set forth in claim 1 wherein said 
formulation has a pH between 2.5 and 6.0. 
11. A method of assaying peroxidase activity in a test 
sample using the formulation of claim 1, comprising the 
steps of: ' 
introducing said test sample into an assaying environ 
ment; ' 
exposing said test sample to said formulation; 
incubating said test sample and formulation mixture; 
and 
examining said test sample and formulation mixture 
for the presence or absence of a colored product. 
12. A process for the preparation of a formulation for 
the detection and determination of peroxidase activity, 
comprising the steps of: 
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forming a ?rst solution by dissolving a chromatic 
compound in a water miscible organic solvent; 
forming a second solution by preparing an aqueous 
acidic buffer solution and adding in any order a 
stabilizing agent selected from a group consisting 
of bacitracin, bacitracin precursors, bacitracin 
components derived by hydrolysis and mixtures 
thereof and a peroxide; and 
mixing said ?rst and second solutions to form said 
formulation. 
13. The process of claim 12, wherein said water-mis 
cible organic solvent is selected from a group consisting 
of dioxane, tetrahydrofuran, dimethyl sulfoxide, di 
methyl formamide and mixtures thereof. 
14. The process of claim 12, wherein said chromatic 
compound is selected from a group consisting of tet 
raalkylbenzidine, salts of tctraalkylbenzidine, and mix 
tures thereof. 
15. The process of claim 12, wherein said chromatic 
compound is 3,3’, 5,5’-tetramethylbenzidine. 
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16. The process of claim 12, wherein said aqueous 
buffer solution is formed using an acidic buffer. 
17. The process of claim 16, wherein said acidic 
buffer is selected from a group consisting of citrate, 
acetate, phosphate and mixtures thereof. 
18. The process of claim 12, wherein a ratio between 
said ?rst solution and said second solution is between 
1:99 and 35:65 volume percent. 
19. The process of claim 12, wherein a ?nal concen 
tration of said chromatic compound is between 1.0 mM 
and 1.75 mM. 
20. The process of claim 12, wherein a ?nal concen 
tration of said stabilizing agent is between 0.5 mM and 
2 mM. 
21. The process of claim 12, wherein a ?nal concen 
tration of said peroxide is between 2.0'mM and 10.0 
mM. 
22. The process as in claim 12, wherein said formula 
tion has a pH of between 2.5 and 6.0. 
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